Rifapentine has 39 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Doravirine, Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate, Ranolazine. Patients taking Rifapentine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 39
- Contraindicated
- 5
- Major
- 10
- Moderate
- 20
Contraindicated (5)
- Rifapentine + Doravirine— Co-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to…
- Rifapentine + Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate— Co-administration decreases doravirine plasma concentrations and is contraindicated. At least a 4-week cessation period …
- Rifapentine + Ranolazine— CYP3A inducer. Do not use with ranolazine extended-release tablets.
- Rifapentine + Rilpivirine— Coadministration is contraindicated due to decreased rilpivirine plasma concentrations and loss of virologic response.
- Rifapentine + Rilpivirine Hydrochloride— Coadministration is contraindicated. Induces CYP3A, resulting in decreased rilpivirine plasma concentrations and loss of…
Major (10)
- Rifapentine + Alafenamide— Decreases tenofovir alafenamide concentrations. Coadministration is not recommended.
- Rifapentine + Axitinib— Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.
- Rifapentine + Cabotegravir— UGT1A1 inducer that decreases cabotegravir plasma concentrations significantly. Coadministration expected to reduce cabo…
- Rifapentine + Emtricitabine And Tenofovir Alafenamide— Decreases TAF concentration. Coadministration with DESCOVY is not recommended.
- Rifapentine + Erlotinib— CYP3A4 inducer decreases erlotinib exposure. Increase erlotinib dosage if co-administration is unavoidable.
- Rifapentine + Erlotinib Hydrochloride— CYP3A4 inducer decreases erlotinib exposure. Increase erlotinib dosage if co-administration is unavoidable.
- Rifapentine + Irinotecan Hydrochloride— Strong CYP3A4 inducer substantially reduces exposure to irinotecan and its active metabolite SN-38. Avoid use or substit…
- Rifapentine + Mao Inhibitors— Rifapentine induces CYP450 enzymes, causing significant decrease in plasma concentrations and loss of therapeutic effect…
- Rifapentine + Oral Contraceptives— Rifapentine may reduce the effectiveness of hormonal contraceptives. Alternative non-hormonal or barrier methods recomme…
- Rifapentine + Protease Inhibitors— Rifapentine induces CYP450 enzymes, causing significant decrease in plasma concentrations and loss of therapeutic effect…
Moderate (20)
- Rifapentine + Cabozantinib— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
- Rifapentine + Chloramphenicol— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Ciprofloxacin— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Clarithromycin— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Dapsone— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Disopyramide— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Doxycycline— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Flibanserin— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Rifapentine + Fluconazole— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Haloperidol— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Itraconazole— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Ketoconazole— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Mexiletine— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Phenobarbital— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Phenytoin— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Quinidine— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Quinine— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Rapamycin— Weak/moderate CYP3A4/P-gp inducer that may decrease sirolimus concentrations. Monitor and adjust dosage as needed.
- Rifapentine + Tocainide— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.
- Rifapentine + Warfarin— Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.